New KCA issueKCA 3:2, article 5, figure2KCA 3:1, article 2, figure 1KCA 3:1, article 1, figure 1Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (2:1)Perioperative Systemic Therapy for Metastatic Renal Cell CarcinomaRationale to prime the immune system

Following on from the launch Kidney Cancer in summer 2017, we are now pleased to announce publication the latest issue of the journal. Click on the banner image to go straight to the issue!

This research article examines the role microRNAs (miRNAS) in the progression of cancer types, including clear cell renal cell carcinoma (ccRCC). Visual Left: Venn diagram of the prognostic miRNAs (pink) identified by Kaplan-Meier analysis and the master regulator (blue) of the prognostic genes in the Stanford dataset. Visual Right: Identified 96 miR-22 target genes. From: Gong, et al., Kidney Cancer, vol. 3, no. 2, pp. 119-132, 2019

This review examines cell-free circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma. Visual illustrates circulating cell-free DNA (cfDNA) and ctDNA found in serum and plasma fractions from blood. From: Hahn, et al., Kidney Cancer, vol. 3, no. 1, pp. 7-13, 2019

This review examines radiation therapy in the treatment of renal cell carcinoma with an aim to expand the discussion on treatment options. Visual is an example of a patient treated with stereotactic ablative radiotherapy for a renal tumor. From: Choi and Yu, Kidney Cancer, vol. 3, no. 1, pp. 1-6, 2019

This study indicates that 4LT appears to have activity in mRCC patients. The figure shows total number of patients receiving the therapies (A); with (B) indicating therapies given to patients who received 4LT. From: Stukalin, et al., Kidney Cancer, vol. 2, no. 1, pp. 31–36, 2018.

Renal cell carcinoma's disease biology: inactivated VHL gene leads to overexpression of HIF. Genes activated by HIF transcript growth factors such as VEGF, PDGF and FGF. From: Maia et al., Kidney Cancer, vol. 1, no. 1, pp. 15-29, 2017

Rationale to prime the immune system with PD-1 blockade prior to nephrectomy. From: Harshman et al., Kidney Cancer, vol. 1, no. 1, pp. 31-40, 2017

Welcome to Kidney Cancer

Editorial Board

Primo Nery Lara

Primo N. Lara Jr, MD

University of California Davis Comprehensive Cancer Center
Sacramento, CA, USA

Email: kca@iospress.com

Peter Mulder

Peter Mulders, MD, PhD

Radboud UMC Nijmegen,The Netherlands

Email: kca@iospress.com

 

Submission Guidelines

SUBMIT YOUR MANUSCRIPT HERE

SUBMISSION OF MANUSCRIPTS:

AUTHOR INSTRUCTIONS

Authors are requested to submit their manuscript electronically to the online submission system msTracker. Note that the manuscript should be uploaded as one file with tables and figures included.

Tweets

No front page content has been created yet.